CB-03-01 Powder

Description

Product Information

Product Overview

CB-03-01, otherwise called Clascoterone, is a steroidal compound. The product is widely studied in dermatological and biochemical research. This is due to its selective interaction with androgen receptors. The mentioned receptors are typically found in skin and hair follicle environments. [1]

Provided as a high-purity crystalline powder, this research-grade material is ideal for controlled laboratory studies. It is commonly utilized for in vitro assays and mechanistic investigations of androgen-related pathways.

Why Choose BC9 to Buy CB-03-01 Online?

BC9 supplies high-quality research materials, backed by rigorous standards. This is BC9’s way of supporting scientific progress. As a leading research-focused company, BC9 is renowned for providing reliable compounds essential for advanced study and innovation. In turn, scientists, experts, and research enthusiasts rely on BC9 for their various lab studies.

Mechanism of Action

CB-03-01 functions as a topical-selective androgen receptor antagonist. This was observed within laboratory models. It is believed to bind to androgen receptors (AR) in cellular environments. Findings suggest that it competes with endogenous androgens. One example of these is dihydrotestosterone (DHT). [2]

As it occupies these receptors, the molecule can modulate downstream signaling pathways. These may be involved in:

• Sebaceous gland activity [3]
• Hair follicle cell regulation [4]
• Local androgen-responsive gene expression [5]

Potential Research Applications

CB-03-01 powder has been the subject of various research studies. These include fields such as:

Androgen Receptor Biology

• Characterizing AR binding behavior
• Studying competitive inhibition

Dermatological Research

• Examining cellular responses in sebocytes and follicular keratinocytes
• Investigating androgen-regulated pathways in skin models

Biochemical and Pharmacological Profiling

• Determining receptor affinity
• Evaluating metabolic stability and degradation patterns
• Conducting comparative studies with other AR modulators

Mechanistic Studies

• Understanding transcriptional changes downstream of AR modulation
• Exploring non-systemic AR interactions in topical-like environments

IMPORTANT:

CB-03-01 is classified as a research compound. Thus, it is not safe for human consumption. Buy CB-03-01 online for research purposes only.

Frequently Asked Questions

Is CB-03-01 intended for human use?

No. BC9 sells its CB-03-01 powder for laboratory research purposes only. It is not intended for human use, medical use, or cosmetic use.

What purity levels are provided?

Each batch of CB-03-01 from BC9 is ≥98%. This product is verified by HPLC. A COA is provided for transparency purposes.

Can this compound be utilized for formulation studies?

It may be used in non-clinical, bench-scale formulation research. This is recommended as long as it remains within the scope of laboratory studies. Plus, the studies do not involve creating products intended for human consumption.

How should CB-03-01 be stored?

Store CB-03-01 in a sealed container. Place it in a cool and dry environment away from direct light. Observe standard chemical handling and laboratory safety protocols.

References

1. Celasco, G., Moro, L., Bozzella, R., Ferraboschi, P., Bartorelli, L., Quattrocchi, C., & Nicoletti, F. (2011). Biological profile of Cortexolone 17A-Propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung, 54(12), 881–886. https://doi.org/10.1055/s-0031-1297043
2. Hebert, A., Thiboutot, D., Gold, L. S., Cartwright, M., Gerloni, M., Fragasso, E., & Mazzetti, A. (2020). Efficacy and safety of topical Clascoterone Cream, 1%, for treatment in patients with facial acne. JAMA Dermatology, 156(6), 621. https://doi.org/10.1001/jamadermatol.2020.0465
3. ClinicalTrials.gov. (n.d.). https://clinicaltrials.gov/study/NCT02608450
4. Dhillon, S. (2020). Clascoterone: first approval. Drugs, 80(16), 1745–1750. https://doi.org/10.1007/s40265-020-01417-6
5. Rosette, C., Agan, F. J., Rosette, N., Mazzetti, A., Moro, L., & Gerloni, M. (2020). The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade. Molecular Cancer Therapeutics, 19(11), 2256–2266. https://doi.org/10.1158/1535-7163.mct-19-1137